PHOENIX, AZ--(Marketwire - Dec 21, 2011) - Kedem Pharmaceuticals Inc. (OTCBB: [ KDMP ]), a specialty pharmaceutical company with focus on sublingual and orodispersable drugs announced today they began trading under symbol KDMP.ob and their new website is [ www.kedempharmaceuticals.com ].

Dr. Hassan Salari, Chairman and CEO, stated, "Kedem is properly capitalized and focused on our goals to commercialize our sublingual drug delivery system. We will further our communication with the public markets in the New Year as business developments are achieved." He added, "The Company has made a number of progress and achievements in its business development through 2011, and will update the shareholders in due course in 2012."

About Kedem Pharmaceuticals Inc. - KDMP.ob is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.

Forward-looking Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to un foreseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.